 Daniel Stephenson
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sphingolipids | 13 | 2026 | 83 | 1.480 |
Why?
| | Erythrocytes | 13 | 2025 | 748 | 1.410 |
Why?
| | Ceramides | 9 | 2024 | 117 | 1.080 |
Why?
| | Blood Preservation | 8 | 2025 | 346 | 1.020 |
Why?
| | Hemolysis | 8 | 2025 | 242 | 0.940 |
Why?
| | Eicosanoids | 8 | 2025 | 58 | 0.890 |
Why?
| | Pre-Eclampsia | 2 | 2023 | 206 | 0.780 |
Why?
| | Anemia, Sickle Cell | 5 | 2026 | 318 | 0.670 |
Why?
| | Metabolomics | 7 | 2025 | 732 | 0.650 |
Why?
| | Biomarkers | 8 | 2026 | 4295 | 0.650 |
Why?
| | Erythrocyte Transfusion | 4 | 2025 | 225 | 0.610 |
Why?
| | Premature Birth | 1 | 2023 | 388 | 0.570 |
Why?
| | Neural Stem Cells | 3 | 2026 | 168 | 0.560 |
Why?
| | Group IV Phospholipases A2 | 5 | 2023 | 46 | 0.540 |
Why?
| | Tears | 4 | 2025 | 27 | 0.530 |
Why?
| | Lipids | 5 | 2024 | 707 | 0.490 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 3 | 2026 | 49 | 0.460 |
Why?
| | Mice | 29 | 2026 | 18329 | 0.440 |
Why?
| | Cycloserine | 2 | 2024 | 5 | 0.430 |
Why?
| | Glucosephosphate Dehydrogenase | 2 | 2025 | 70 | 0.430 |
Why?
| | Blood Donors | 3 | 2025 | 144 | 0.420 |
Why?
| | Fluid Therapy | 2 | 2026 | 155 | 0.420 |
Why?
| | Metabolome | 4 | 2025 | 388 | 0.420 |
Why?
| | Sepsis | 3 | 2026 | 664 | 0.410 |
Why?
| | Mice, Inbred NOD | 3 | 2024 | 613 | 0.410 |
Why?
| | Oxidative Stress | 9 | 2026 | 1356 | 0.390 |
Why?
| | Resuscitation | 2 | 2026 | 310 | 0.370 |
Why?
| | Animals | 34 | 2026 | 38030 | 0.360 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2025 | 143 | 0.360 |
Why?
| | Wound Healing | 3 | 2026 | 355 | 0.350 |
Why?
| | Vision Disorders | 2 | 2025 | 179 | 0.340 |
Why?
| | Mice, Inbred C57BL | 12 | 2026 | 5983 | 0.340 |
Why?
| | Glycolysis | 4 | 2025 | 340 | 0.320 |
Why?
| | Autophagy | 2 | 2025 | 291 | 0.310 |
Why?
| | Signal Transduction | 4 | 2025 | 5216 | 0.310 |
Why?
| | Sphingomyelin Phosphodiesterase | 3 | 2025 | 27 | 0.300 |
Why?
| | Hypoxia | 3 | 2026 | 1199 | 0.280 |
Why?
| | Multiple Sclerosis | 2 | 2024 | 489 | 0.280 |
Why?
| | Aspirin | 2 | 2023 | 406 | 0.280 |
Why?
| | Erythrocyte Aging | 2 | 2025 | 12 | 0.280 |
Why?
| | Group VI Phospholipases A2 | 2 | 2024 | 6 | 0.270 |
Why?
| | Sphingosine | 2 | 2026 | 47 | 0.260 |
Why?
| | Retinal Degeneration | 2 | 2024 | 40 | 0.260 |
Why?
| | Cornea | 2 | 2026 | 154 | 0.260 |
Why?
| | Meibomian Glands | 2 | 2023 | 15 | 0.250 |
Why?
| | Humans | 42 | 2026 | 145474 | 0.240 |
Why?
| | Persian Gulf Syndrome | 1 | 2025 | 18 | 0.230 |
Why?
| | Glutathione | 2 | 2025 | 370 | 0.230 |
Why?
| | Chondroitin Sulfates | 1 | 2026 | 35 | 0.230 |
Why?
| | Hemoglobins | 2 | 2025 | 386 | 0.230 |
Why?
| | Cellular Senescence | 2 | 2025 | 226 | 0.230 |
Why?
| | Niacinamide | 1 | 2026 | 104 | 0.230 |
Why?
| | Corneal Injuries | 1 | 2026 | 42 | 0.230 |
Why?
| | Lipogenesis | 1 | 2026 | 62 | 0.230 |
Why?
| | Glycocalyx | 1 | 2025 | 30 | 0.230 |
Why?
| | Isotope Labeling | 1 | 2026 | 82 | 0.220 |
Why?
| | Neuroacanthocytosis | 1 | 2025 | 5 | 0.220 |
Why?
| | Carrier Proteins | 2 | 2020 | 728 | 0.220 |
Why?
| | Aging, Premature | 1 | 2025 | 16 | 0.220 |
Why?
| | Receptor, Adenosine A2B | 1 | 2025 | 65 | 0.220 |
Why?
| | Motor Disorders | 1 | 2025 | 17 | 0.220 |
Why?
| | Polymorphism, Genetic | 2 | 2025 | 614 | 0.220 |
Why?
| | Cation Transport Proteins | 1 | 2026 | 118 | 0.220 |
Why?
| | Caffeine | 1 | 2025 | 74 | 0.220 |
Why?
| | Proteostasis | 1 | 2025 | 27 | 0.220 |
Why?
| | Placenta | 2 | 2023 | 786 | 0.220 |
Why?
| | Acute Kidney Injury | 2 | 2024 | 875 | 0.210 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2025 | 34 | 0.210 |
Why?
| | Vasoconstrictor Agents | 1 | 2025 | 150 | 0.210 |
Why?
| | Macrophages | 2 | 2024 | 1507 | 0.210 |
Why?
| | Glucose Transporter Type 1 | 1 | 2024 | 48 | 0.210 |
Why?
| | Cachexia | 1 | 2025 | 74 | 0.210 |
Why?
| | Pyruvate Kinase | 1 | 2024 | 28 | 0.210 |
Why?
| | Vesicular Transport Proteins | 1 | 2025 | 85 | 0.210 |
Why?
| | Oleic Acid | 1 | 2024 | 40 | 0.210 |
Why?
| | Anaplasma phagocytophilum | 1 | 2024 | 3 | 0.210 |
Why?
| | Cysteine | 1 | 2025 | 211 | 0.210 |
Why?
| | Myelodysplastic Syndromes | 1 | 2026 | 165 | 0.210 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2024 | 66 | 0.210 |
Why?
| | Lipid Metabolism | 3 | 2024 | 529 | 0.210 |
Why?
| | Blood Group Antigens | 1 | 2023 | 15 | 0.200 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2023 | 15 | 0.200 |
Why?
| | Female | 25 | 2026 | 78844 | 0.200 |
Why?
| | Proteome | 2 | 2025 | 514 | 0.200 |
Why?
| | Carnitine | 1 | 2024 | 91 | 0.200 |
Why?
| | Uric Acid | 1 | 2025 | 167 | 0.200 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2023 | 28 | 0.200 |
Why?
| | Eye Injuries | 1 | 2024 | 53 | 0.200 |
Why?
| | Calcium | 2 | 2019 | 1190 | 0.190 |
Why?
| | Insulin-Secreting Cells | 2 | 2024 | 392 | 0.190 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 572 | 0.190 |
Why?
| | Male | 25 | 2026 | 72842 | 0.190 |
Why?
| | Arginine | 1 | 2024 | 264 | 0.190 |
Why?
| | Dry Eye Syndromes | 1 | 2024 | 56 | 0.190 |
Why?
| | Fluoxetine | 1 | 2023 | 56 | 0.190 |
Why?
| | PTEN Phosphohydrolase | 1 | 2024 | 165 | 0.190 |
Why?
| | Apoptosis | 4 | 2024 | 2440 | 0.190 |
Why?
| | Hematopoietic Stem Cells | 1 | 2026 | 435 | 0.190 |
Why?
| | Mustard Gas | 1 | 2024 | 77 | 0.190 |
Why?
| | Exercise Tolerance | 1 | 2025 | 283 | 0.190 |
Why?
| | Cholesterol | 1 | 2024 | 408 | 0.180 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 242 | 0.180 |
Why?
| | Disease Models, Animal | 7 | 2026 | 4560 | 0.180 |
Why?
| | Lung Neoplasms | 3 | 2025 | 2664 | 0.180 |
Why?
| | Mass Spectrometry | 3 | 2026 | 730 | 0.180 |
Why?
| | Mast Cells | 1 | 2023 | 147 | 0.180 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2024 | 3922 | 0.180 |
Why?
| | Brain Injuries, Traumatic | 2 | 2025 | 453 | 0.180 |
Why?
| | Mice, Inbred BALB C | 1 | 2024 | 1261 | 0.180 |
Why?
| | Light | 1 | 2024 | 403 | 0.170 |
Why?
| | Inflammation | 6 | 2024 | 2878 | 0.170 |
Why?
| | Mitochondria | 2 | 2026 | 992 | 0.170 |
Why?
| | Neoplasm Proteins | 1 | 2025 | 441 | 0.170 |
Why?
| | Drosophila Proteins | 1 | 2023 | 213 | 0.170 |
Why?
| | Drosophila melanogaster | 1 | 2023 | 237 | 0.170 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 919 | 0.170 |
Why?
| | Head Injuries, Closed | 1 | 2021 | 49 | 0.170 |
Why?
| | Energy Metabolism | 2 | 2024 | 935 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2024 | 1140 | 0.170 |
Why?
| | Retinal Diseases | 1 | 2022 | 101 | 0.170 |
Why?
| | Affective Symptoms | 1 | 2021 | 53 | 0.170 |
Why?
| | Adipose Tissue | 1 | 2025 | 645 | 0.160 |
Why?
| | Movement Disorders | 1 | 2021 | 69 | 0.160 |
Why?
| | Depression | 3 | 2025 | 1546 | 0.160 |
Why?
| | Macrophages, Peritoneal | 1 | 2020 | 89 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 171 | 0.160 |
Why?
| | Cadherins | 1 | 2021 | 200 | 0.150 |
Why?
| | Macular Degeneration | 1 | 2022 | 191 | 0.150 |
Why?
| | Altitude | 1 | 2023 | 463 | 0.150 |
Why?
| | Antirheumatic Agents | 1 | 2022 | 307 | 0.150 |
Why?
| | Kidney | 2 | 2024 | 1497 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2025 | 956 | 0.140 |
Why?
| | Reperfusion Injury | 1 | 2021 | 293 | 0.140 |
Why?
| | Phosphatidylcholines | 1 | 2019 | 130 | 0.140 |
Why?
| | Cell Death | 1 | 2020 | 382 | 0.140 |
Why?
| | Muscle, Skeletal | 2 | 2025 | 1789 | 0.130 |
Why?
| | Necrosis | 1 | 2018 | 244 | 0.130 |
Why?
| | Melanoma | 1 | 2024 | 759 | 0.130 |
Why?
| | Neutrophils | 1 | 2023 | 1124 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2023 | 699 | 0.130 |
Why?
| | Oxygen | 1 | 2022 | 978 | 0.130 |
Why?
| | Brain Concussion | 2 | 2024 | 644 | 0.130 |
Why?
| | Cell Differentiation | 1 | 2024 | 2046 | 0.120 |
Why?
| | Disease | 1 | 2017 | 96 | 0.120 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 919 | 0.120 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 257 | 0.120 |
Why?
| | Mice, Knockout | 4 | 2026 | 3124 | 0.110 |
Why?
| | Middle Aged | 10 | 2026 | 36215 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 890 | 0.110 |
Why?
| | Liver | 1 | 2024 | 1896 | 0.110 |
Why?
| | Brain | 2 | 2025 | 2947 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5904 | 0.110 |
Why?
| | Lysophospholipids | 2 | 2026 | 80 | 0.110 |
Why?
| | Hypertension, Pulmonary | 1 | 2026 | 1957 | 0.110 |
Why?
| | Adult | 10 | 2025 | 40777 | 0.100 |
Why?
| | Aging | 1 | 2024 | 1969 | 0.100 |
Why?
| | Sphingomyelins | 2 | 2024 | 22 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1189 | 0.100 |
Why?
| | Cytokines | 3 | 2026 | 2067 | 0.100 |
Why?
| | Quantitative Trait Loci | 2 | 2025 | 378 | 0.090 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2025 | 254 | 0.090 |
Why?
| | Adipocytes | 2 | 2025 | 223 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2188 | 0.090 |
Why?
| | Pregnancy | 2 | 2023 | 7202 | 0.090 |
Why?
| | Aged | 7 | 2026 | 26153 | 0.090 |
Why?
| | Asthma | 1 | 2024 | 1797 | 0.090 |
Why?
| | Mammals | 2 | 2024 | 286 | 0.090 |
Why?
| | Oxidation-Reduction | 2 | 2025 | 1067 | 0.090 |
Why?
| | Adenosine Triphosphate | 2 | 2024 | 500 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2023 | 6447 | 0.080 |
Why?
| | Thrombin | 2 | 2023 | 172 | 0.080 |
Why?
| | Retina | 2 | 2024 | 326 | 0.080 |
Why?
| | Pilot Projects | 2 | 2025 | 1891 | 0.070 |
Why?
| | Sex Factors | 2 | 2025 | 2105 | 0.070 |
Why?
| | Sex Characteristics | 2 | 2024 | 782 | 0.070 |
Why?
| | Neoplasms | 1 | 2024 | 2906 | 0.070 |
Why?
| | Proteomics | 2 | 2025 | 1188 | 0.070 |
Why?
| | Genome-Wide Association Study | 2 | 2024 | 1407 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2021 | 1368 | 0.060 |
Why?
| | Fibroblasts | 2 | 2024 | 1025 | 0.060 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2026 | 26 | 0.060 |
Why?
| | Cell Movement | 2 | 2022 | 959 | 0.060 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2026 | 74 | 0.060 |
Why?
| | Syndecan-1 | 1 | 2025 | 43 | 0.060 |
Why?
| | Oculomotor Nerve Injuries | 1 | 2025 | 2 | 0.060 |
Why?
| | Lipolysis | 1 | 2025 | 44 | 0.060 |
Why?
| | Glutamine | 1 | 2026 | 109 | 0.060 |
Why?
| | Carbon Isotopes | 1 | 2026 | 143 | 0.060 |
Why?
| | Electroretinography | 1 | 2025 | 50 | 0.060 |
Why?
| | Glucose Transport Proteins, Facilitative | 1 | 2025 | 16 | 0.050 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2024 | 13 | 0.050 |
Why?
| | Erythroid Cells | 1 | 2024 | 8 | 0.050 |
Why?
| | Reticulocytes | 1 | 2024 | 17 | 0.050 |
Why?
| | Enzyme Activators | 1 | 2024 | 9 | 0.050 |
Why?
| | Erythroblasts | 1 | 2024 | 18 | 0.050 |
Why?
| | Phosphofructokinases | 1 | 2024 | 7 | 0.050 |
Why?
| | Solute Carrier Family 22 Member 5 | 1 | 2024 | 7 | 0.050 |
Why?
| | Hexokinase | 1 | 2024 | 18 | 0.050 |
Why?
| | Lipid Peroxidation | 1 | 2025 | 167 | 0.050 |
Why?
| | Erythropoiesis | 1 | 2024 | 57 | 0.050 |
Why?
| | Simvastatin | 1 | 2024 | 59 | 0.050 |
Why?
| | Serine C-Palmitoyltransferase | 1 | 2024 | 8 | 0.050 |
Why?
| | 2,3-Diphosphoglycerate | 1 | 2023 | 32 | 0.050 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2024 | 17 | 0.050 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2024 | 29 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 3542 | 0.050 |
Why?
| | Melanoma, Experimental | 1 | 2024 | 109 | 0.050 |
Why?
| | Golgi Apparatus | 1 | 2024 | 99 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2026 | 226 | 0.050 |
Why?
| | Eyelids | 1 | 2024 | 41 | 0.050 |
Why?
| | Mice, SCID | 1 | 2024 | 369 | 0.050 |
Why?
| | Mechlorethamine | 1 | 2024 | 52 | 0.050 |
Why?
| | Isoenzymes | 1 | 2024 | 294 | 0.050 |
Why?
| | Autocrine Communication | 1 | 2023 | 38 | 0.050 |
Why?
| | Docosahexaenoic Acids | 1 | 2024 | 88 | 0.050 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2026 | 611 | 0.050 |
Why?
| | Pyruvates | 1 | 2022 | 23 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 471 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2024 | 762 | 0.050 |
Why?
| | Inosine | 1 | 2022 | 14 | 0.050 |
Why?
| | Feedback | 1 | 2023 | 180 | 0.050 |
Why?
| | Rabbits | 1 | 2024 | 652 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2023 | 300 | 0.050 |
Why?
| | Microglia | 1 | 2025 | 270 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 866 | 0.050 |
Why?
| | Autophagosomes | 1 | 2022 | 20 | 0.050 |
Why?
| | Iron | 1 | 2025 | 357 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2024 | 335 | 0.050 |
Why?
| | Sputum | 1 | 2024 | 302 | 0.040 |
Why?
| | Prospective Studies | 2 | 2025 | 8057 | 0.040 |
Why?
| | Arachidonic Acids | 1 | 2022 | 42 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2023 | 315 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2023 | 450 | 0.040 |
Why?
| | Behavior, Animal | 1 | 2025 | 519 | 0.040 |
Why?
| | Phosphates | 1 | 2022 | 177 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2026 | 776 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2019 | 2507 | 0.040 |
Why?
| | Disease Resistance | 1 | 2021 | 29 | 0.040 |
Why?
| | Lysosomes | 1 | 2022 | 131 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2022 | 65 | 0.040 |
Why?
| | Blotting, Western | 1 | 2024 | 1179 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2024 | 1266 | 0.040 |
Why?
| | Brain Chemistry | 1 | 2021 | 119 | 0.040 |
Why?
| | Ischemia | 1 | 2024 | 422 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2024 | 409 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2025 | 583 | 0.040 |
Why?
| | Adenosine | 1 | 2022 | 255 | 0.040 |
Why?
| | Cell Survival | 1 | 2024 | 1100 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 820 | 0.040 |
Why?
| | Cisplatin | 1 | 2022 | 345 | 0.040 |
Why?
| | Glucose | 1 | 2026 | 1048 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 477 | 0.040 |
Why?
| | Naphthalenes | 1 | 2020 | 54 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2062 | 0.040 |
Why?
| | Thromboxane B2 | 1 | 2019 | 23 | 0.040 |
Why?
| | Ketones | 1 | 2020 | 50 | 0.040 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2019 | 35 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2022 | 271 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2023 | 447 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2024 | 1508 | 0.040 |
Why?
| | Tensile Strength | 1 | 2019 | 98 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2021 | 274 | 0.040 |
Why?
| | Cations, Divalent | 1 | 2019 | 47 | 0.040 |
Why?
| | Immunotherapy | 1 | 2024 | 666 | 0.040 |
Why?
| | Dinoprostone | 1 | 2019 | 180 | 0.040 |
Why?
| | Cytosol | 1 | 2019 | 213 | 0.040 |
Why?
| | Cytoplasm | 1 | 2019 | 254 | 0.040 |
Why?
| | Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2018 | 14 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2018 | 64 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2018 | 35 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2018 | 53 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2018 | 105 | 0.030 |
Why?
| | Cell Line | 1 | 2024 | 2823 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2019 | 376 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2019 | 408 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 302 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 407 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3623 | 0.030 |
Why?
| | Fear | 1 | 2021 | 368 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2024 | 11772 | 0.030 |
Why?
| | Models, Biological | 1 | 2024 | 1764 | 0.030 |
Why?
| | Collagen | 1 | 2019 | 457 | 0.030 |
Why?
| | Fatty Acids | 1 | 2020 | 457 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2024 | 849 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1023 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2158 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 588 | 0.030 |
Why?
| | Diet | 1 | 2024 | 1277 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2864 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2024 | 3413 | 0.030 |
Why?
| | Up-Regulation | 1 | 2018 | 847 | 0.030 |
Why?
| | Cell Cycle | 1 | 2018 | 598 | 0.030 |
Why?
| | Neurons | 1 | 2024 | 1649 | 0.030 |
Why?
| | Stroke | 1 | 2024 | 1270 | 0.030 |
Why?
| | Skin | 1 | 2019 | 753 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1852 | 0.030 |
Why?
| | Phosphorylation | 1 | 2018 | 1707 | 0.030 |
Why?
| | Time Factors | 1 | 2025 | 7123 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 6013 | 0.020 |
Why?
| | Veterans | 1 | 2025 | 1635 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2238 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 8333 | 0.020 |
Why?
| | Child | 2 | 2023 | 22707 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3155 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 6066 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 14218 | 0.020 |
Why?
| | Adolescent | 1 | 2020 | 22529 | 0.010 |
Why?
|
|
Stephenson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|